137 related articles for article (PubMed ID: 4019569)
21. Influence of peroral charcoal on pharmacokinetics and intestinal toxicity of intravenously given methotrexate.
Scheufler E; Bos I
Arch Int Pharmacodyn Ther; 1983 Feb; 261(2):180-5. PubMed ID: 6838279
[TBL] [Abstract][Full Text] [Related]
22. Increased excretion of thyroxine by feeding activated charcoal to Syrian hamsters.
Bergman F; Halvorsen P; Van der Linden W
Acta Endocrinol (Copenh); 1967 Nov; 56(3):521-4. PubMed ID: 6072469
[No Abstract] [Full Text] [Related]
23. Superactivated charcoal versus cholestyramine for cholesterol lowering: a randomized cross-over trial.
Park GD; Spector R; Kitt TM
J Clin Pharmacol; 1988 May; 28(5):416-9. PubMed ID: 3292601
[TBL] [Abstract][Full Text] [Related]
24. Altered effect of 3% dietary cholestyramine on plasma lipids and biliary bile acid output in the pregnant rat.
Innis SM
Am J Obstet Gynecol; 1984 Nov; 150(6):742-4. PubMed ID: 6496596
[TBL] [Abstract][Full Text] [Related]
25. Cholestyramine orally administered to patients with erythropoietic protoporphyria results in urinary excretion of protoporphyrin: to be explained by the Herbst-Volkheimer effect?
Beukeveld GJ; Wolthers BG
Clin Chim Acta; 1995 Jan; 233(1-2):119-26. PubMed ID: 7758200
[No Abstract] [Full Text] [Related]
26. [Managing methotrexate toxicity: a case report].
Fernández Megía MJ; Alós Almiñana M; Terol Castera MJ
Farm Hosp; 2004; 28(5):371-4. PubMed ID: 15504095
[TBL] [Abstract][Full Text] [Related]
27. Kinetics of 7-hydroxy-methotrexate after high-dose methotrexate therapy.
Erttmann R; Bielack S; Landbeck G
Cancer Chemother Pharmacol; 1985; 15(2):101-4. PubMed ID: 3874719
[TBL] [Abstract][Full Text] [Related]
28. Comparison of the effects of cholestyramine and aluminium hydroxide on the biliary bile acid excretion in rats. An experimental model for the depletion of bile acids in bile.
Gregus Z; Barth A; Fischer E; Zaumseil J; Klinger W; Varga F
Acta Biol Med Ger; 1980; 39(6):705-9. PubMed ID: 7456933
[TBL] [Abstract][Full Text] [Related]
29. Effect of activated charcoal on the pharmacokinetics of high-dose methotrexate.
Gadgil SD; Damle SR; Advani SH; Vaidya AB
Cancer Treat Rep; 1982 May; 66(5):1169-71. PubMed ID: 7083219
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics of methotrexate and 7-hydroxy-methotrexate in plasma and bone marrow of children receiving low-dose oral methotrexate.
Sonneveld P; Schultz FW; Nooter K; Hählen K
Cancer Chemother Pharmacol; 1986; 18(2):111-6. PubMed ID: 3791556
[TBL] [Abstract][Full Text] [Related]
31. The effect of colestipol and cholestyramine on ibuprofen bioavailability in man.
al-Meshal MA; el-Sayed YM; al-Balla SR; Gouda MW
Biopharm Drug Dispos; 1994 Aug; 15(6):463-71. PubMed ID: 7993984
[TBL] [Abstract][Full Text] [Related]
32. Chronic effect of oral cholestyramine, a bile salt sequestrant, and exogenous cholecystokinin on insulin release in rats.
Kogire M; Gomez G; Uchida T; Ishizuka J; Greeley GH; Thompson JC
Pancreas; 1992; 7(1):15-20. PubMed ID: 1557341
[TBL] [Abstract][Full Text] [Related]
33. Influence of cholestyramine on the pharmacokinetics of cerivastatin.
Mück W; Ritter W; Frey R; Wetzelsberger N; Lücker PW; Kuhlmann J
Int J Clin Pharmacol Ther; 1997 Jun; 35(6):250-4. PubMed ID: 9208341
[TBL] [Abstract][Full Text] [Related]
34. Drug-cholestyramine interactions. II. Influence of cholestyramine on GI absorption of sodium fusidate.
Johns WH; Bates TR
J Pharm Sci; 1972 May; 61(5):735-9. PubMed ID: 5035781
[No Abstract] [Full Text] [Related]
35. A controlled clinical trial of cholestyramine in the treatment of gastric ulcer.
Black RB; Rhodes J; Davies GT; Gravelle H; Sweetnam P
Gastroenterology; 1971 Dec; 61(6):821-5. PubMed ID: 5125683
[No Abstract] [Full Text] [Related]
36. Effect of DMPS and various adsorbents on the arsenic excretion in guinea-pigs after injection with As2O3.
Reichl FX; Hunder G; Liebl B; Fichtl B; Forth W
Arch Toxicol; 1995; 69(10):712-7. PubMed ID: 8572930
[TBL] [Abstract][Full Text] [Related]
37. Effect of cholestyramine on bile acid pattern and synthesis during administration of ursodeoxycholic acid in man.
Rust C; Sauter GH; Oswald M; Büttner J; Kullak-Ublick GA; Paumgartner G; Beuers U
Eur J Clin Invest; 2000 Feb; 30(2):135-9. PubMed ID: 10651838
[TBL] [Abstract][Full Text] [Related]
38. Formation and elimination of 7-hydroxymethotrexate in the rat in vivo after methotrexate administration.
Bremnes RM; Slørdal L; Wist E; Aarbakke J
Cancer Res; 1989 May; 49(9):2460-4. PubMed ID: 2706634
[TBL] [Abstract][Full Text] [Related]
39. Methotrexate Associated Renal Impairment Is Related to Delayed Elimination of High-Dose Methotrexate.
Yang SL; Zhao FY; Song H; Shen DY; Xu XJ
ScientificWorldJournal; 2015; 2015():751703. PubMed ID: 26185782
[TBL] [Abstract][Full Text] [Related]
40. Methotrexate is excreted into the bile by canalicular multispecific organic anion transporter in rats.
Masuda M; I'izuka Y; Yamazaki M; Nishigaki R; Kato Y; Ni'inuma K; Suzuki H; Sugiyama Y
Cancer Res; 1997 Aug; 57(16):3506-10. PubMed ID: 9270020
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
